Repaglinide

Mechanism of Action

Repaglinide is an oral antidiabetic medication that belongs to the class of drugs known as meglitinides. It is primarily used in the treatment of type 2 diabetes mellitus.

The mechanism of action of repaglinide involves targeting the pancreatic beta cells and enhancing insulin secretion in response to glucose levels. It specifically acts on the ATP-sensitive potassium channels (KATP channels) located on the beta cells of the pancreas.

When blood glucose levels rise after a meal, glucose enters the pancreatic beta cells through glucose transporters. This increase in intracellular glucose concentration leads to the closing of ATP-sensitive potassium channels, which causes the cell membrane to depolarize. The depolarization triggers the influx of calcium ions through voltage-gated calcium channels, resulting in the release of insulin from the beta cells into the bloodstream.

Repaglinide works by binding to the ATP-sensitive potassium channels on the pancreatic beta cells, which results in their closure and subsequent depolarization of the cell membrane. This action promotes the entry of calcium ions through voltage-gated calcium channels, triggering insulin release. By stimulating insulin secretion, repaglinide helps to lower blood glucose levels in individuals with type 2 diabetes.

Indication

Repaglinide is indicated for the treatment of type 2 diabetes mellitus. It is prescribed to individuals who are unable to control their blood glucose levels through diet and exercise alone. Repaglinide is used as an adjunct to lifestyle modifications, including diet and exercise, to help manage and improve glycemic control in patients with type 2 diabetes.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Repaglinide API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Repaglinide API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.